Source comparison
AOD 9604 vs Semaglutide for Weight Loss
This is the most common comparison question. The honest answer: semaglutide has vastly superior evidence. Beta-3 AR lipolysis (fat cells) GLP-1 receptor agonist (brain + gut) FDA approved No Yes (June 2021) Largest trial 536 patients (failed primary endpoint)
This comparison does not assign a generated winner or score.
- This is the most common comparison question. The honest answer: semaglutide has vastly superior evidence.
- Beta-3 AR lipolysis (fat cells)
- GLP-1 receptor agonist (brain + gut)
- FDA approved
- No
- Yes (June 2021)
- Largest trial
- 536 patients (failed primary endpoint)
- 1,961 patients (STEP 1, succeeded)
- Weight loss
- Not significant vs placebo
- 14.9% body weight at 68 weeks
- Administration
- Daily subcutaneous injection
- Weekly subcutaneous injection
- Side effects
- Indistinguishable from placebo
- 44% nausea, 31% diarrhea
- Appetite suppression
- None
- Strong
- Monthly cost
- $40-80 (research grade)
- $199-499 (compounded)
- Muscle preservation
- Neutral
- Some lean mass loss
- Cardiovascular benefit
- Not studied
- 20% MACE reduction (SELECT trial)
- AOD 9604's advantages are limited to three areas: lower side effects, lower cost, and no appetite suppression (some users prefer maintaining normal appetite). For patients seeking proven pharmaceutical fat loss, semaglutide and tirzepatide are backed by large randomized controlled trials showing 15-22% weight loss.
- See our semaglutide dosage chart and tirzepatide dosage chart for FDA-approved weight loss medication dosing. Compare costs with our cost calculator.